IQVIA Holdings Inc. (NYSE:IQV) Position Cut by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 37.1% in the 4th quarter, Holdings Channel reports. The fund owned 438,306 shares of the medical research company’s stock after selling 258,394 shares during the period. Loomis Sayles & Co. L P’s holdings in IQVIA were worth $86,132,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. Advisors Asset Management Inc. increased its stake in IQVIA by 74.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 2,845 shares of the medical research company’s stock valued at $674,000 after buying an additional 1,213 shares during the period. Intech Investment Management LLC acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $223,000. Algert Global LLC bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $514,000. Larson Financial Group LLC lifted its stake in IQVIA by 745.1% during the third quarter. Larson Financial Group LLC now owns 431 shares of the medical research company’s stock valued at $102,000 after purchasing an additional 380 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in IQVIA by 4.8% during the third quarter. Fisher Asset Management LLC now owns 7,398 shares of the medical research company’s stock worth $1,753,000 after buying an additional 341 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IQV shares. UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Performance

Shares of IQV opened at $179.91 on Thursday. The firm has a market cap of $31.72 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company’s fifty day moving average is $193.92 and its 200-day moving average is $207.10. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $179.12 and a 12 month high of $253.84.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.